Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.

@article{Komura2016ResistanceTD,
  title={Resistance to docetaxel in prostate cancer is associated with androgen receptor activation and loss of KDM5D expression.},
  author={Kazumasa Komura and Seong Ho Jeong and Kunihiko Hinohara and Fangfang Qu and Xiaodong Wang and Masayuki Hiraki and Haruhito Azuma and Gwo-Shu Lee and Philip W. Kantoff and Christopher J. Sweeney},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  year={2016},
  volume={113 22},
  pages={6259-64}
}
The androgen receptor (AR) plays an essential role in prostate cancer, and suppression of its signaling with androgen deprivation therapy (ADT) has been the mainstay of treatment for metastatic hormone-sensitive prostate cancer for more than 70 y. Chemotherapy has been reserved for metastatic castration-resistant prostate cancer (mCRPC). The Eastern Cooperative Oncology Group-led trial E3805: ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate… CONTINUE READING
Highly Cited
This paper has 20 citations. REVIEW CITATIONS
Recent Discussions
This paper has been referenced on Twitter 4 times over the past 90 days. VIEW TWEETS
12 Citations
32 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 32 references

Similar Papers

Loading similar papers…